About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

First Study in Humans With GSK206136 | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT01059578

First Study in Humans With GSK206136

This is the first study in humans with GSK206136 to evaluate what effects: good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream an...

Lead sponsor: GlaxoSmithKline•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

Age

18 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy males aged 18-45 years, limited to 25-40 years of age for PET section

Exclusion Criteria

•The subject has a positive: drug/alcohol, Hepatitis, HIV screen..
•The subject has a history of psychiatric illness suicidal attempts or behaviour.
•Abuse of alcohol.
•Clinically significant laboratory, ECG abnormality;
•The subject has recently received an investigational.
•Use of prescription or non-prescription drugs,
•History or presence of allergy to the study drug or drugs of this class,
•Donation of more than 500 mL blood within the 90 days before dosing.
•An unwillingness of male subjects to comply with contraceptive requirements
•Average daily caffeine intake exceeding Protocol requirements.

Related studies

The Impact of Melatonin Lotion on Sleep and Mental Health

NCT06768749 · Sleep Problems, Depressive Disorder and Anxiety Disorders

COMPLETEDPhase 1

A First Time in Human Study of GSK586529 in Healthy Volunteers

NCT00703547 · Depressive Disorder and Anxiety Disorders

COMPLETEDPhase 1

A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

NCT00513565 · Depressive Disorder and Anxiety Disorders

COMPLETEDPhase 1

Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic

NCT01424384 · Depressive Disorder and Anxiety Disorders

COMPLETEDPhase 1

Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

NCT00435695 · Healthy Subjects, Depressive Disorder and Anxiety Disorders

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 10, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment33

Start dateMay 2006

Last updatedAug 10, 2017

Condition

Depressive Disorder and Anxiety Disorders

Locations shown

GSK Investigational Site

London

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 10, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions